Birchview Capital’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $160K | Hold |
28,000
| – | – | 0.16% | 61 |
|
2025
Q1 | $228K | Hold |
28,000
| – | – | 0.2% | 50 |
|
2024
Q4 | $264K | Hold |
28,000
| – | – | 0.21% | 52 |
|
2024
Q3 | $299K | Hold |
28,000
| – | – | 0.26% | 47 |
|
2024
Q2 | $278K | Hold |
28,000
| – | – | 0.26% | 45 |
|
2024
Q1 | $330K | Hold |
28,000
| – | – | 0.27% | 43 |
|
2023
Q4 | $397K | Hold |
28,000
| – | – | 0.31% | 38 |
|
2023
Q3 | $340K | Hold |
28,000
| – | – | 0.29% | 38 |
|
2023
Q2 | $352K | Hold |
28,000
| – | – | 0.26% | 44 |
|
2023
Q1 | $311K | Hold |
28,000
| – | – | 0.24% | 43 |
|
2022
Q4 | $342K | Sell |
28,000
-10,000
| -26% | -$122K | 0.24% | 40 |
|
2022
Q3 | $397K | Hold |
38,000
| – | – | 0.28% | 43 |
|
2022
Q2 | $408K | Hold |
38,000
| – | – | 0.3% | 40 |
|
2022
Q1 | $360K | Hold |
38,000
| – | – | 0.26% | 46 |
|
2021
Q4 | $439K | Hold |
38,000
| – | – | 0.28% | 47 |
|
2021
Q3 | $363K | Hold |
38,000
| – | – | 0.25% | 49 |
|
2021
Q2 | $366K | Hold |
38,000
| – | – | 0.22% | 52 |
|
2021
Q1 | $375K | Hold |
38,000
| – | – | 0.22% | 45 |
|
2020
Q4 | $877K | Hold |
38,000
| – | – | 0.51% | 30 |
|
2020
Q3 | $537K | Hold |
38,000
| – | – | 0.36% | 30 |
|
2020
Q2 | $573K | Hold |
38,000
| – | – | 0.35% | 33 |
|
2020
Q1 | $351K | Hold |
38,000
| – | – | 0.31% | 34 |
|
2019
Q4 | $370K | Hold |
38,000
| – | – | 0.27% | 40 |
|
2019
Q3 | $305K | Hold |
38,000
| – | – | 0.2% | 37 |
|
2019
Q2 | $474K | Hold |
38,000
| – | – | 0.29% | 34 |
|
2019
Q1 | $517K | Hold |
38,000
| – | – | 0.32% | 29 |
|
2018
Q4 | $364K | Hold |
38,000
| – | – | 0.34% | 32 |
|
2018
Q3 | $459K | Buy |
38,000
+4,000
| +12% | +$48.3K | 0.3% | 38 |
|
2018
Q2 | $531K | Hold |
34,000
| – | – | 0.36% | 30 |
|
2018
Q1 | $511K | Buy |
34,000
+24,000
| +240% | +$361K | 0.34% | 30 |
|
2017
Q4 | $144K | Hold |
10,000
| – | – | 0.08% | 37 |
|
2017
Q3 | $151K | Buy |
+10,000
| New | +$151K | 0.08% | 36 |
|